Five things for pharma marketers to know: Monday, March 7, 2016

Photo credit: e-Magine Art/Creative Commons

1. The European Medicines Agency launched a new program aimed at speeding up approval of new drugs that treat unmet medical needs. The program is called PRIME, which stands for PRIority MEdicines. About 100 drugs are expected to go through the new program each year. (Reuters)

2. AbbVie and Boehringer Ingelheim said they will collaborate to develop and commercialize BI 655066, which is in late-stage development as a treatment for psoriasis. The drugmakers are also examining the experimental drug's use in Crohn's disease, psoriatic arthritis, and asthma.

3. The FDA approved CSL Behring's Idelvion, a hemophilia B drug. The treatment can provide a 14-day dosing regimen to protect against bleeding. (PharmaTimes)

4. GlaxoSmithKline said a long-term study showed that Nucala, its asthma drug, which is approved in the U.S. and Europe, has a similar safety profile during a 52-week period compared to previous studies. The therapy received FDA approval in November. (Reuters)

5. A federal advisory panel's decision to pick certain influenza virus strains for vaccines in the 2016-17 flu season has stemmed concerns about a possible supply shortage. Drugmakers had said different strains could have affected their production schedule. (Modern Healthcare)